336 related articles for article (PubMed ID: 16419908)
1. [Viral safety concept: application to blood and blood products].
Trouvin JH
Rev Prat; 2005 Nov; 55(18):2033-8. PubMed ID: 16419908
[TBL] [Abstract][Full Text] [Related]
2. Considerations in performing virus spiking experiments and process validation studies.
Darling AJ
Dev Biol Stand; 1993; 81():221-9. PubMed ID: 8174806
[TBL] [Abstract][Full Text] [Related]
3. Process changes and their effect on process evaluation for viral clearance.
Marcus-Sekura C
Dev Biol Stand; 1996; 88():125-30. PubMed ID: 9119123
[TBL] [Abstract][Full Text] [Related]
4. Viral safety of biological products in WHO policy.
Grachev VP
Dev Biol Stand; 1991; 75():241-6. PubMed ID: 1794628
[TBL] [Abstract][Full Text] [Related]
5. Viral safety evaluation of plasma-derived therapeutic products.
Farshid M
Dev Biol (Basel); 2004; 118():11-5. PubMed ID: 15645668
[TBL] [Abstract][Full Text] [Related]
6. Blood transfusion in Europe: basic principles for initial and continuous training in transfusion medicine: an approach to an European harmonisation.
Mueller MM; Seifried E
Transfus Clin Biol; 2006 Nov; 13(5):282-5; quiz 286-9. PubMed ID: 17196864
[TBL] [Abstract][Full Text] [Related]
7. Transposition of the Blood Directive into national law--the perspective of Portugal.
Gonçalves MH; Muon MC; Gonçalves Jd
Transfus Clin Biol; 2005 Feb; 12(1):18-20. PubMed ID: 15814287
[TBL] [Abstract][Full Text] [Related]
8. European Regulatory guidance on virus safety of recombinant proteins, monoclonal antibodies and plasma derived medicinal products.
Celis P; Silvester G
Dev Biol (Basel); 2004; 118():3-10. PubMed ID: 15645667
[TBL] [Abstract][Full Text] [Related]
9. [Stating technical requirements and deferral criteria for whole blood donation].
Danic B
Transfus Clin Biol; 2005 Jul; 12(3):287-9. PubMed ID: 15963750
[TBL] [Abstract][Full Text] [Related]
10. [Transfusion medicine in unified Europe].
Grigutsch V
Infusionsther Transfusionsmed; 1994 Nov; 21 Suppl 3():12-5. PubMed ID: 7841774
[TBL] [Abstract][Full Text] [Related]
11. Blood safety--a focus on plasma derivatives in Mainland China.
Zhu YM
Dev Biol (Basel); 2007; 127():175-81. PubMed ID: 17486891
[TBL] [Abstract][Full Text] [Related]
12. Blood supply safety: an NHLBI perspective.
Glynn SA
Transfusion; 2008 Aug; 48(8):1541-4. PubMed ID: 18713102
[No Abstract] [Full Text] [Related]
13. Viral validation of the manufacturing process of high purity albumin from placentas.
Grandgeorge M; Véron JL
Dev Biol Stand; 1993; 81():237-44. PubMed ID: 8174808
[TBL] [Abstract][Full Text] [Related]
14. Transfusion safety: Where are we today?
Luban NL
Ann N Y Acad Sci; 2005; 1054():325-41. PubMed ID: 16339681
[TBL] [Abstract][Full Text] [Related]
15. Bovine serum: reducing the variables through the use of donor herds.
Rolleston WB
Dev Biol Stand; 1999; 99():79-86. PubMed ID: 10404879
[TBL] [Abstract][Full Text] [Related]
16. Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: precautionary measures and efficacy of manufacturing processes in prion removal.
Flan B; Arrabal S
Transfus Clin Biol; 2007 May; 14(1):51-62. PubMed ID: 17540602
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of national regulations concerning blood safety across Europe.
Mascaretti L; James V; Barbara J; Cárdenas JM; Blagoevska M; Haracić M; Rossi U
Transfus Med; 2004 Apr; 14(2):105-12. PubMed ID: 15113375
[TBL] [Abstract][Full Text] [Related]
18. Collection of source material from remunerated donors.
Rodell MB
Dev Biol Stand; 1993; 81():57-64. PubMed ID: 8174821
[TBL] [Abstract][Full Text] [Related]
19. Virus validation procedures: practical aspects.
Minor PD
Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S10-2. PubMed ID: 7495959
[TBL] [Abstract][Full Text] [Related]
20. At what stage should virus inactivation be carried out?
Dorner F; Barrett PN; Eibl J
Dev Biol Stand; 1993; 81():137-43. PubMed ID: 8174796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
